[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349771-105":59,"doc-detail-349771-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","induction-chemoimmunotherapy-followed-by-concurrent-radiotherapy-in-patients-with-locally-advanced-esophageal-cancer-a-single-arm-phase-2-trial","Induction Chemoimmunotherapy Followed by Concurrent Radiotherapy in Patients with Locally Advanced Esophageal Cancer - A Single-Arm Phase 2 Trial","","Background: This phase II trial prospectively assessed the efficacy and safety of induction chemoimmunotherapy followed by sequential concurrent chemoradiotherapy plus immunotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who were ineligible for surgery. Methods: Forty-four patients received 2 cycles of induction therapy with paclitaxel and carboplatin/nedaplatin plus a PD-1 inhibitor, then concurrent radiotherapy with two additional cycles and maintenance immunotherapy up to 1 year. Primary endpoint was progression-free survival (PFS).",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/induction-chemoimmunotherapy-followed-by-concurrent-radiotherapy-in-patients-with-locally-advanced-esophageal-cancer-a-single-arm-phase-2-trial/349771/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/induction-chemoimmunotherapy-followed-by-concurrent-radiotherapy-in-patients-with-locally-advanced-esophageal-cancer-a-single-arm-phase-2-trial/349771.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Who were eligible for this phase II trial?","Question",{"text":112,"@type":113},"Patients had locally advanced esophageal squamous cell carcinoma (ESCC) and were ineligible for surgery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatment sequence was evaluated?",{"text":117,"@type":113},"Induction chemoimmunotherapy was followed by sequential concurrent chemoradiotherapy, then immune maintenance therapy for up to one year.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the primary and key secondary endpoints?",{"text":121,"@type":113},"The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), safety, and quality of life (QoL).",{"name":123,"@type":110,"acceptedAnswer":124},"How did the safety and quality of life outcomes look?",{"text":125,"@type":113},"Treatment-related adverse events were generally mild, though 38.6% experienced grade ≥3 events, mainly hematologic toxicity. Quality-of-life assessments in surviving patients indicated favorable overall function and well-being.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},349771,1790128127,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Induction chemoimmunotherapy followed by concurrent radiotherapy in patients with locally advanced esophageal cancer: a single-arm phase 2 trial  \nHui Chen1, Zeyuan Liu2,3, Wang Zheng1, Xinchen Sun1, Xiaolin Ge*, 1, Xiaojie Xia*, 1,  \n1Department of Radiation Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China 2Department of Radiation Oncology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210000, China 3Department of Oncology, Kangda College of Nanjing Medical University, Haizhou District, Lianyungang 222000, China  \n*Corresponding authors. Xiaojie Xia, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, Jiangsu 210029, China. [E-mail:](E-mail: doctorxiaxiaojie@163.com)[ doctorxiaxiaojie@163.com](E-mail: doctorxiaxiaojie@163.com); Xiaolin Ge, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, Jiangsu 210029, China. E-mail: [doctorxlg@163.com](doctorxlg@163.com).  \nAbstract  \nBackground: This phase II trial prospectively assessed the efficacy and safety of induction chemoimmunotherapy followed by sequential concurrent chemoradiotherapy plus immunotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who were ineligible for surgery.  \nMethods: Forty-four patients received 2 cycles of induction therapy (paclitaxel plus carboplatin/nedaplatin combined with a PD-1 inhibitor), followed by concurrent radiotherapy with two additional cycles of chemoimmunotherapy and subsequent immune maintenance therapy for up to 1 year. The primary endpoint was progression-free survival (PFS); the secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), safety, and quality of life (QoL) .  \nResults: At the data cut-off point (median follow-up: 25.5 months), both the ORR and DCR were 95. 5% . The median PFS was 26 months (95% CI, 14.8-37.2), and the median OS was 29 months (95% CI, 23.0-35.0) . The 1- , 2- , and 3-year PFS rates were 75.0%, 51.9%, and 40.4%, respectively, and the OS rates were 81.8%, 63. 1%, and 42.0%, respectively. Distant metastasis represented the main failure mode (64 .0%) . Treatment-related adverse events were generally mild; moreover, 17 patients (38 .6%) experienced grade ≥3 events, primarily involving hematologic toxicity (14/17) . Severe immune-related adverse events were rarely observed. QoL assessment in surviving patients ( n = 21) indicated favorable overall function and well-being.  \nConclusions: This regimen of induction chemoimmunotherapy followed by concurrent chemoradiotherapy and maintenance immunotherapy demonstrated promising survival outcomes, a manageable safety profile, and a preserved QoL, thereby offering a viable nonsurgical alternative for patients with locally advanced ESCC.  \nKey words: esophageal cancer; immunotherapy; induction therapy; survival; quality of life.  \nImplications for Practice  \nThis study demonstrated that induction chemoimmunotherapy followed by concurrent chemoradiotherapy and maintenance immunotherapy provides promising survival outcomes with a manageable safety profile for patients with locally advanced esophageal squamous cell carcinoma who are ineligible for surgery. This regimen, which is associated with high response rates and prolonged survival while preserving quality of life, offers a viable nonsurgical treatment alternative. These findings support the integration of this multimodal approach into clinical practice, thus potentially changing the standard of care for this patient population by improving long-term disease control and tolerability.  \nIntroduction  \nEsophageal cancer ranks seventh throughout the world in terms of cancer-related deaths. A study focusing on the distribution of esophageal cancer in Asia revealed that the incidence rate in China is approximately 224 000 cases per 382 000 individuals,1,2 thus demonstrating this ","cbCaisr9MlxHYfwi","https://ap.wps.com/l/cbCaisr9MlxHYfwi","pdf",486712,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Implications for Practice\n# Introduction","[{\"question\":\"Who were eligible for this phase II trial?\",\"answer\":\"Patients had locally advanced esophageal squamous cell carcinoma (ESCC) and were ineligible for surgery.\"},{\"question\":\"What treatment sequence was evaluated?\",\"answer\":\"Induction chemoimmunotherapy was followed by sequential concurrent chemoradiotherapy, then immune maintenance therapy for up to one year.\"},{\"question\":\"What were the primary and key secondary endpoints?\",\"answer\":\"The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), safety, and quality of life (QoL).\"},{\"question\":\"How did the safety and quality of life outcomes look?\",\"answer\":\"Treatment-related adverse events were generally mild, though 38.6% experienced grade ≥3 events, mainly hematologic toxicity. Quality-of-life assessments in surviving patients indicated favorable overall function and well-being.\"}]","Induction Chemoimmunotherapy Followed by Concurrent Radiotherapy in Patients with Locally Advanced Esophageal Cancer - A Single-Arm Phase 2 Trial | PDF",1790085473,23,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18b37fb44c41da2953964aeb7940a9bb.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05f5742cf5563ae0aeff1ead813c332d.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45f2498b5a83f0d44f85a3f0a393efea.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f5690004c5097af304516e36ac2a428.webp",980,1287]